tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kemp Dolliver, 23 are a BUY (88.46%), 3 are a HOLD (11.54%).
Analyst Kemp Dolliver, currently employed at BROOKLINE, carries an average stock price target met ratio of 39.39% that have a potential upside of 23.03% achieved within 69 days.
Kemp Dolliver’s has documented 47 price targets and ratings displayed on 13 stocks. The coverage is on Healthcare, Energy sectors.
Most recent stock forecast was given on VRCA, Verrica Pharmaceuticals at 18-Dec-2025.
Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for MNPR (MONOPAR THERAPEUTICS) at 9/25/2025. The price target of $93 was fulfilled within 7 days with a profit of $15.56 (20.09%) receiving and performance score of 28.7.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 10-Mar-2020
$18
$10.16 (129.59%)
$25
8 months 13 days ago
(26-Jan-2026)
5/11 (45.45%)
$9.85 (120.86%)
440
Buy Since 27-Jul-2021
$26
$18.16 (231.63%)
$3
1 years 6 months 26 days ago
(13-Mar-2025)
0/2 (0%)
$16.45 (172.25%)
Buy Since 13-Jan-2023
$1.25
3 years 8 months 26 days ago
(13-Jan-2023)
0/1 (0%)
$-3.24 (-72.16%)
Buy Since 30-Sep-2020
$22.5
$12.36 (121.89%)
$45
4 years 6 months 28 days ago
(11-Mar-2022)
1/2 (50%)
$14.32 (175.06%)
118
Buy Since 14-Aug-2020
$52.5
$46.64 (795.90%)
6 years 1 months 25 days ago
(14-Aug-2020)
0/1 (0%)
$18.45 (54.19%)
What Year was the first public recommendation made by Kemp Dolliver?
